Should cholesterol-lowering medications be available in Canada without a prescription?

Rashid, Shahidur

doi:10.1016/s0828-282x(07)70742-0

Cited by 5 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the Agency for Healthcare Research and Quality, over $19.7 billion dollars were spent on statins in the US outpatient population from 2000 to 2005, and over 29.7 million people are taking statins in the USA 5. In Canada it is estimated that over 12 million prescriptions for statins are dispensed every year, making statins the most prescribed drug in the country 6 7. Certain adverse effects are well-known, and it is recommended that patients be monitored for signs of myopathy and liver dysfunction and preventive measures have been proposed 8…”

Section: Introductionmentioning

confidence: 99%

Statins and the risk of interstitial lung disease: a cohort study

Saad

Camus²,

Suissa

et al. 2013

Thorax

View full text Add to dashboard Cite

Background Case reports have suggested that the use of statins may be associated with an increase in the risk of interstitial lung disease (ILD). Methods Within a large cohort of users of respiratory medications identified in the Quebec health administrative databases during 1990-2005, we carried out a nested case-control analysis of the relationship between statins and the risk of ILD as defined by specialist visits or hospitalisations. Results The cohort included over 1.4 million patients, of which 6665 possible or probable cases of ILD were identified during follow-up. These were compared with 26 660 controls matched for age, gender and calendar time. After adjustment for confounders and comorbid conditions, there was no association between current use of statins and risk of ILD (adjusted OR 0.99, 95% CI 0.91 to 1.08). The results were similar when any use of statins within the previous 1 or 2 years was considered or when the analysis was limited to more definite cases. Conclusions This large cohort study did not find an association between statin use and the incidence of ILD. BACKGROUND

show abstract

Section: Introductionmentioning

confidence: 99%

Statins and the risk of interstitial lung disease: a cohort study

Saad

Camus²,

Suissa

et al. 2013

Thorax

View full text Add to dashboard Cite

show abstract

“…Statins are still not used as aggressively as recommended by the guidelines in high-risk primary prevention populations, let alone those in lower-risk groups (13,18). One major reason is the issue of adverse effects, which may result in significant numbers of total affected individuals in clinics, due to the large numbers in the overall primary prevention group.…”

mentioning

confidence: 99%

Statins and primary prevention: Is all the evidence in?

Rashid

2008

Canadian Journal of Cardiology

Self Cite

View full text Add to dashboard Cite

A Neuromuscular Approach to Statin-Related Myotoxicity

Baker

Samjoo

2008

Can. j. neurol. sci.

View full text Add to dashboard Cite

RÉSUMÉ: Approche neuromusculaire de la myotoxicité due aux statines. Près de 95% des patients qui reçoivent une statine tolèrent bien ce traitement hypocholestérolémiant, sans réactions indésirables. Cependant, les complications musculaires sont relativement fréquentes parce qu'un grand nombre de patients reçoivent ce traitement à cause de son efficacité pour abaisser le taux de lipoprotéines de faible densité et pour diminuer l'incidence d'événements cardiovasculaires. Comme on connaît mal leur pathophysiologie, il est difficile d'identifier les patients à risque de développer une myotoxicité sous statine. Il y a de plus en plus de cas ou de séries de cas rapportés qui impliquent les statines dans l'exacerbation de myopathies tant acquises que génétiques. Nous présentons un algorithme concernant la conduite à tenir le cas échéant, qui énumère différentes co-morbidités pouvant potentialiser les effets indésirables des statines sur le muscle. De plus, nous discutons d'une démarche rationnelle pour identifier les patients qui sont les plus susceptibles de bénéficier d'une biopsie musculaire. Les travaux en cours permettront de définir dans quelle mesure les patients qui sont intolérants aux statines sont porteurs de myopathies métaboliques récessives ou de myopathies acquises pré-symptomatiques. L'importance croissante de la pharmacogénomique jouera sans doute un rôle dans le domaine de la recherche sur la myopathie due aux statines dans les prochaines années. Cette information est d'une grande importance pour établir des stratégies de diagnostic et de traitement.

show abstract

Should cholesterol-lowering medications be available in Canada without a prescription?

Cited by 5 publications

References 23 publications

Statins and the risk of interstitial lung disease: a cohort study

Statins and the risk of interstitial lung disease: a cohort study

Statins and primary prevention: Is all the evidence in?

A Neuromuscular Approach to Statin-Related Myotoxicity

Contact Info

Product

Resources

About